Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3286763 | 0.82 | PTGS2 (0.42) | ALDH1A1TMIGD3KDRRAB9AGRM5 | |
| SCHEMBL3292421 | 0.81 | PTGS2 (0.41) | ALDH1A1MAPTTMIGD3KDRRAB9A | |
| SCHEMBL3292092 | 0.80 | HPGD (0.37) | ALDH1A1KDM4EMAPTTSHRCYP2C19 | |
| SCHEMBL3285310 | 0.80 | PTGS2 (0.43) | ALDH1A1MAPTTMIGD3KDRNPC1 | |
| SCHEMBL3288851 | 0.79 | PTGS2 (0.45) | ALDH1A1TMIGD3KDRNPC1RAB9A | |
| SCHEMBL4576936 | 0.79 | ADORA3 (0.49) | ALDH1A1MAPTCYP1A2TMIGD3NPC1 | |
| SCHEMBL3288330 | 0.78 | PTGS2 (0.40) | ALDH1A1MAPTTMIGD3KDRNPC1 | |
| SCHEMBL4576705 | 0.78 | PTGS2 (0.41) | ALDH1A1KDM4EMAPTPPARGNCOA2 | |
| SCHEMBL4576546 | 0.78 | PTGS2 (0.49) | ALDH1A1TMIGD3KDRNPC1RAB9A | |
| SCHEMBL13325326 | 0.78 | RAB9A (0.47) | ALDH1A1KDM4EMAPTCYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718686-B2 | Imidazole variants as modulators of GABA receptor for the treatment of GI disorders | ASTRAZENECA AB (SE) | 2010-05-18 | — | — | US | claimed |
| US-20080269216-A1 | Imidazole Variants as Modulators of Gaba Receptor For the Treatment of Gi Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | claimed |
| US-7718686-B2 | Imidazole variants as modulators of GABA receptor for the treatment of GI disorders | ASTRAZENECA AB (SE) | 2010-05-18 | — | — | US | disclosed |
| US-7718686-B2 | Imidazole variants as modulators of GABA receptor for the treatment of GI disorders | ASTRAZENECA AB (SE) | 2010-05-18 | — | — | US | disclosed |
| US-7718686-B2 | Imidazole variants as modulators of GABA receptor for the treatment of GI disorders | ASTRAZENECA AB (SE) | 2010-05-18 | — | — | US | disclosed |
| US-20080269216-A1 | Imidazole Variants as Modulators of Gaba Receptor For the Treatment of Gi Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269216-A1 | Imidazole Variants as Modulators of Gaba Receptor For the Treatment of Gi Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269216-A1 | Imidazole Variants as Modulators of Gaba Receptor For the Treatment of Gi Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269216-A1 | Imidazole Variants as Modulators of Gaba Receptor For the Treatment of Gi Disorders | GABRB1, GABBR2, GABBR1 | ALDH1A1 1225/4885KDM4E 2917/4885MAPT 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.